FibroBiologics Sells $1.2M Convertible Debenture at 15% Discount to Peak One
FBLG sits 82% above its 52-week low of $0.62 on light trading volume (0.3× avg).
Summary
FibroBiologics raised $1.02 million in net cash via a $1.2 million convertible debenture with Peak One, carrying a $0.78 conversion price and a $1.08 million interim payment due April 2027.
Key Events · Financing and Capital Events · FBLG
-
Convertible Debenture Closed
Issued $1.2M principal debenture to Peak One Opportunity Fund for $1.02M cash, a 15% original issue discount, plus a $20,000 non-accountable fee.
-
Conversion Terms
Fixed conversion price of $0.78 per share, only convertible upon an Event of Default; capped at 1,671,094 shares under Nasdaq Exchange Cap and 4.99% beneficial ownership blocker.
-
Repayment Schedule
Interim payment of $1.08M due April 8, 2027, $60,000 due July 8, 2027, and remaining balance at maturity October 8, 2027; default accelerates 120% of principal.
-
Cash Sweep Provision
Holder may require 50% of any cash proceeds above $1.5M aggregate threshold from equity, debt, warrant conversions, or asset sales to repay the debenture.
Analysis · FBLG · Life Sciences
On October 8, 2026, FibroBiologics closed a $1.2 million convertible debenture with Peak One Opportunity Fund, receiving only $1.02 million in cash after a 15% original issue discount and a $20,000 fee. The debenture carries a fixed conversion price of $0.78 per share — below the current $1.13 market price — but is only convertible upon an Event of Default. The company must repay $1.08 million by April 8, 2027, a near-term cash obligation that exceeds the $3.5 million cash balance reported in its last 10-Q. Against the backdrop of a going concern warning, a Nasdaq delisting determination, and a material weakness disclosed in July 2026, this financing extends runway but adds a senior repayment obligation with default acceleration at 120% of principal. The 125,000 commitment shares and potential conversion of up to 1,671,094 shares represent additional dilution pressure on a stock already facing a 67% dilution overhang from the June 2026 private placement.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FBLG was trading at $1.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4M. The 52-week trading range was $0.62 to $10.33. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.